Advancing COPD Care: Applying Latest Guidance in Clinical Practice - CME - Guideline Central

CME

Title
Advancing COPD Care: Applying Latest Guidance in Clinical Practice
Link
Description
Chronic obstructive pulmonary disease (COPD) continues to pose a significant global health burden, with exacerbations contributing to reduced quality of life, hospitalizations, and mortality. While inhaled triple therapy remains a cornerstone of treatment, many patients—particularly those with eosinophilic inflammation—continue to experience exacerbations. This enduring activity explores evolving concepts in COPD pathophysiology, specifically the role of type 2 (T2) inflammation, and reviews current evidence supporting the use of biologic therapies as targeted interventions. Drawing on pivotal trials of biologic agents, expert faculty discuss the clinical utility of biomarkers like blood eosinophil count in guiding treatment escalation. Emphasis is placed on the integration of new GOLD 2025 recommendations, real-world clinical cases, and practical strategies for the use of biologics in COPD. This activity is designed to equip clinicians with actionable knowledge to personalize COPD care and reduce the burden of exacerbations through precision medicine.
Target Audience
The target audience for this program will include pulmonologists, allergists/immunologists, and critical care medicine physicians (MDs, DOs), nurse practitioners (NPs) and physician associates/physician assistants (PAs) practicing in these specialties; as well as primary care clinicians (MDs, DOs, NPs, and PAs) and geriatricians caring for patients with or at risk for COPD.
Learning Objectives
  • Review the relationship between inflammation, exacerbation, and disease progression in COPD noting the underlying pathophysiology
  • Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD, including patient populations and outcomes
  • Integrate the use of biologic agents into the management of patients with COPD based on guidelines and clinical evidence for new and emerging agents
Estimated Duration
60 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Pulmonology, Geriatric Medicine, Critical Care, Allergy and Immunology, Primary Care
Keywords
chronic obstructive pulmonary disease (COPD), COPD
Disclosures and Disclaimers
Disclosures: All relevant financial relationships for anyone with the ability to control the content of this educational activity have been mitigated. Disclaimer: Content is current as of the date this activity was released. The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
Accredited Providers
  • National Association for Continuing Education
  • Association for Pulmonary Advanced Practice Providers
Commercial Support
  • Regeneron Pharmaceuticals, Inc
  • Sanofi US
Activity Expiration Date
August 19, 2026
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit1 CreditsACCME- Accreditation Council for Continuing Medical Education
Nursing1 Contact HoursAANP- American Association of Nurse Practitioners
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.